팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2022-11-08 한경바이오인사이트 22년 11월 커버스토리-큐리언트
      2022-10-13 한경바이오인사이트 22년 10월 핫컴퍼니-큐리언트
      2022-10-06 [공지사항] 주식 매매 거래 재개 안내
      2022-08-26 큐리언트 IR 자료(2022.08)
      2022-08-22 큐리언트 텔레그램 채널 오픈 안내
  • Press Release

      2022-11-01 큐리언트, 면역항암제 'Q702'와 키트루다 병용투여 임상 연구자 미팅 개...
      2022-11-01 큐리언트 “2개의 키트루다 병용요법 개발…MSD 인정한 가능성”
      2022-10-05 큐리언트 “1년간 파이프라인 지속 성장…기술이전 본격 추진”
      2022-10-05 큐리언트, 면역항암제 ‘Q702’ 전임상 결과 국제학술지 발표
      2022-09-14 Qurient Announces Collaboration Agreement with MSD to...
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file